1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,560 | 2,800 | 12.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Aclarion erweitert CLARITY-Studie um renommierte Privatpraxis für Wirbelsäulenchirurgie | 1 | Investing.com Deutsch | ||
| Do | Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial | 1 | Investing.com | ||
| Do | Aclarion, Inc.: Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment | 1 | GlobeNewswire (USA) | ||
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 06.05. | Aclarion, Inc.: Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. | 1 | GlobeNewswire (USA) | ||
| 05.05. | Aclarion establishes second trial agreement with Weill Cornell | - | Investing.com | ||
| 05.05. | Aclarion schließt zweite Studienvereinbarung mit Weill Cornell ab | 4 | Investing.com Deutsch | ||
| 05.05. | Aclarion, Inc.: Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine | 1 | GlobeNewswire (USA) | ||
| 30.04. | Aclarion: Scanvolumen der Nociscan-Plattform steigt im ersten Quartal um 196 % | 5 | Investing.com Deutsch | ||
| 30.04. | Aclarion reports 196% jump in Nociscan scan volumes in Q1 | 5 | Investing.com | ||
| 30.04. | Aclarion, Inc.: Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption | 49 | GlobeNewswire (Europe) | Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflowsAdvancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated... ► Artikel lesen | |
| 28.04. | Aclarion, Inc.: Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan | 3 | GlobeNewswire (USA) | ||
| 22.04. | Aclarion authorizes $2.5 million share buyback program | 1 | Investing.com | ||
| 22.04. | Aclarion announces $2.5M stock repurchase plan | 1 | Seeking Alpha | ||
| 22.04. | Aclarion, Inc.: Aclarion Announces $2.5 Million Stock Repurchase Plan | 1 | GlobeNewswire (USA) | ||
| 22.04. | Aclarion, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.04. | Aclarion, Inc.: Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain | 399 | GlobeNewswire (Europe) | Patent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross marginsExpands intellectual property portfolio to 64 issued and pending... ► Artikel lesen | |
| 14.04. | Aclarion, Inc.: Aclarion Receives Pinnacle Award for AI Innovation | 1 | GlobeNewswire (USA) | ||
| 08.04. | Aclarion establishes agreement with Weill Cornell Medicine | 1 | Investing.com | ||
| 07.04. | Aclarion, Inc.: Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video | 1 | GlobeNewswire (USA) | ||
| 24.03. | Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. | 260 | ACCESS Newswire | Stock has declined 99% since its IPOBelieves Neal has repeatedly failed to fulfill his fiduciary responsibilitySince 2021 Neal has received $240,000 Board compensationAccepted 20% pay increase in 2025... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 338,40 | +3,68 % | Unitedhealth im freien Fall: Droht jetzt der nächste große Absturz? - Handeln Sie, bevor es zu spät ist | ||
| INTUITIVE SURGICAL | 365,95 | +2,64 % | INTUITIVE SURGICAL INC in stabiler Marktphase | ||
| THERMO FISHER | 391,40 | +1,90 % | Jim Cramer on Thermo Fisher: "I Think You Can Buy It at This Level" | ||
| TELADOC HEALTH | 5,722 | -2,69 % | Teladoc Health extends rally to seventh straight session, gaining 22% | ||
| ROKU | 108,50 | -0,17 % | Roku to Stream Inaugural Enhanced Games in North America | ||
| INMODE | 11,720 | +0,34 % | InMode LTD.: InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase | YOKNEAM, Israel, May 6, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced... ► Artikel lesen | |
| BAXTER | 14,795 | -0,54 % | BAXTER INTERNATIONAL INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| ATOSSA THERAPEUTICS | 4,680 | -0,43 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| DENTSPLY SIRONA | 9,324 | +0,69 % | DENTSPLY SIRONA Inc.: Dentsply Sirona Reports First Quarter 2026 Results | News Summary Reported net sales of $880 millionDelivered GAAP gross margin of 48.5%, GAAP net loss per share of ($0.05)Achieved adjusted gross margin of 50.7%, adjusted EBITDA margin of 14.7%: adjusted... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| PETMED EXPRESS | 1,872 | -2,70 % | PetMed Express, Inc.: PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channels | DELRAY BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing business as PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced a strategic partnership with... ► Artikel lesen | |
| CENTENE | 50,32 | +5,18 % | Bernstein raises Centene stock price target to $68 on Medicaid outlook | ||
| TANDEM DIABETES | 12,700 | +0,79 % | Benchmark initiates Tandem Diabetes stock with Hold on channel shift | ||
| ORGANON | 11,315 | 0,00 % | Organon & Co.: Europäische Kommission erteilt Marktzulassung für POHERDY (Pertuzumab) von Henlius und Organon, das erste in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab) | Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die Europäische Kommission die Zulassung für POHERDY (Pertuzumab) 420 mg/14 ml Injektion zur intravenösen... ► Artikel lesen | |
| FRESENIUS | 39,520 | -0,90 % | EQS-News: Fresenius SE & Co. KGaA: Exzellenter Jahresauftakt: Fresenius zeigt anhaltend operative Stärke und Resilienz; Ausblick bestätigt | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Quartalsergebnis
Exzellenter Jahresauftakt: Fresenius zeigt anhaltend operative Stärke und Resilienz; Ausblick bestätigt (News... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.